Nuo Therapeutics, Inc. (AURX) financial statements (2020 and earlier)

Company profile

Business Address 209 PERRY PARKWAY,
GAITHERSBURG,, MD 20877
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments01131163
Cash and cash equivalents01131163
Restricted cash and investments   000 
Receivables 000136
Inventory, net of allowances, customer advances and progress billings0000011
Inventory0000011
Prepaid expense    011
Deferred costs     10
Deferred tax assets    (14)(3)
Other current assets      0
Other undisclosed current assets00001142
Total current assets:011332210
Noncurrent Assets
Property, plant and equipment000011(1)
Intangible assets, net (including goodwill)   1033035
Goodwill   2 11
Intangible assets, net (excluding goodwill)   832934
Deferred costs     40
Other noncurrent assets 0000  
Other undisclosed noncurrent assets      2
Total noncurrent assets:0001143436
TOTAL ASSETS:0111475646
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1111798
Accounts payable1000123
Accrued liabilities001126 
Employee-related liabilities     11
Interest and dividends payable00  3  
Other undisclosed accounts payable and accrued liabilities      4
Debt00  35 2
Derivative instruments and hedges, liabilities00     
Deferred revenue and credits  101
Customer advances and deposits   3
Other undisclosed current liabilities     (4) 
Total current liabilities:111142811
Noncurrent Liabilities
Long-term debt and lease obligation     04
Long-term debt, excluding current maturities     04
Liabilities, other than long-term debt  001315
Deferred revenue and credits  111
Other liabilities  0001 
Derivative instruments and hedges, liabilities     303
Other undisclosed noncurrent liabilities      1
Total noncurrent liabilities:  001329
Total liabilities:1112434019
Temporary equity, carrying amount    11 
Stockholders' equity
Stockholders' equity attributable to parent, including:(1)(0)012(37)1526
Preferred stock0000   
Common stock0000000
Additional paid in capital22222118126125117
Accumulated deficit(23)(22)(21)(6)(163)(110)(91)
Other undisclosed stockholders' equity attributable to parent    000
Other undisclosed stockholders' equity      1
Total stockholders' equity:(1)(0)012(37)1527
TOTAL LIABILITIES AND EQUITY:0111475646

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues111 12812
Revenue, net1 12810
Cost of revenue(0)(0)(1) (8)(7)(8)
Cost of goods and services sold(0)(0)(1) (8)(7)(9)
Gross profit:11(0) 413
Operating expenses(2)(3)(15) (45)(24)(21)
Operating loss:(1)(2)(16) (41)(23)(18)
Nonoperating income (expense)0(0)1 (12)5(2)
Investment income, nonoperating    308(0)
Other nonoperating income (expense)(0)01 (0)(0)0
Interest and debt expense (0)(0) (39)  
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)      
Loss from continuing operations before equity method investments, income taxes:(1)(2)(15) (92)(19)(20)
Other undisclosed income from continuing operations before income taxes000 39  
Loss from continuing operations before income taxes:(1)(2)(15) (53)(19)(20)
Income tax expense (benefit) (0)14 0(0)(0)
Other undisclosed loss from continuing operations(0)      
Net loss:(1)(2)(1) (53)(19)(20)
Other undisclosed net income (loss) attributable to parent00(14)    
Net loss available to common stockholders, diluted:(1)(2)(15) (53)(19)(20)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(1)(2)(1) (53)(19)(20)
Comprehensive loss, net of tax, attributable to parent:(1)(2)(1) (53)(19)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: